Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor beta joining 2-1 (TRBJ2-1) is a gene segment in the beta chain locus of the T cell receptor (TCR), encoding a part of the J (joining) region of the TCR beta subunit in humans[1][4][8]. The TCR is formed through somatic V(D)J recombination, in which one Variable (V), one Diversity (D), and one Joining (J) segment are assembled to create a highly diverse repertoire of antigen-specific receptors on T lymphocytes[3][5]. TRBJ2-1 specifically contributes to the CDR3 (complementarity-determining region 3) loop of the TCR beta chain, a region critical for direct peptide-major histocompatibility complex (MHC) contact during antigen recognition[1][3]. While essential for the adaptive immune system and immune repertoire diversity, TRBJ2-1 itself is a gene segment, not a protein or receptor target of drugs, and is not typically considered a therapeutic target[1][8]. Its primary role is in genetic recombination to ensure T cell diversity and proper immune function[5]. If you are looking for information about the functional T cell receptor complex as a therapeutic target, refer to "T cell receptor (TCR), alpha/beta complex" as a canonical entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor beta joining 2-1 (TRBJ2-1).